Lotus will look forward to adding ophthalmic and respiratory products to its growing portfolio after striking a deal to swallow up Teva’s operations in Thailand.

Plus deals from Huadong/Arcutis, SK Bioscience/Novavax, NeuroBio/MThera, CASI/Mundipharma/Acrotech, Amarin/Lotus and Synergy/Livzon.

Struggling antibiotic company will go privare under the agreement. Bayer will employ Acuitas's liquid nanoparticle technology in gene therapies developed by subsidiary Asklepios.

Glenmark is set to roll out its allergic rhinitis nasal spray Ryaltris in three South East Asian countries following an exclusive licensing agreement with Lotus. The company expects Ryaltris to have a significant role to play in its growth over the coming years.